Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

read more